CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma and CANBridge cancel licensing deal for $20m
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma regains China rights to Nerlynx and amends deal with Fabre
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre engagements | NERLYNX
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
